# A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus

> **NCT02773368** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 420 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin degludec/liraglutide
- **DRUG:** insulin glargine

## Key facts

- **NCT ID:** NCT02773368
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-23
- **Primary completion:** 2017-09-26
- **Final completion:** 2017-10-23
- **Target enrollment:** 420 (ACTUAL)
- **Last updated:** 2020-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02773368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02773368, "A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02773368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*